Literature DB >> 11606369

DNA polymerase beta mediates protection of mammalian cells against ganciclovir-induced cytotoxicity and DNA breakage.

M T Tomicic1, R Thust, R W Sobol, B Kaina.   

Abstract

The efficacy of suicide herpes simplex virus-1 thymidine kinase (HSVtk)/ganciclovir (GCV) gene therapy is often limited by intrinsic resistance of tumor cells. Here we show that repair of GCV incorporated in DNA is a factor involved in GCV resistance. A protective role of DNA repair in GCV-induced cell killing is supported by the following findings: (a) GCV-exposed Chinese hamster ovary-HSVtk cells exhibited both reduced repair of GCV and cloning efficiency in the presence of a specific polymerase beta (beta-pol) inhibitor, prunasin; (b) DNA beta-pol-deficient mouse fibroblasts were more sensitive to the cytotoxic, apoptosis-inducing, and genotoxic (DNA breakage and chromosomal aberration-inducing) effects of GCV as compared with wild-type and beta-pol-complemented cell lines; (c) methoxyamine, an inhibitor of beta-pol-dependent short-patch base excision repair, sensitized wild-type and complemented beta-pol cells to GCV, whereas it had no effect on the sensitivity of beta-pol-null cells to GCV. Because methoxyamine-mediated sensitization of beta-pol wild-type and beta-pol-complemented cells to GCV did not reach the level of null cells, we suggest that both beta-pol-dependent short- and long-patch base excision repair are involved in protection of cells to GCV. Some implications for HSVtk/GCV gene therapy are being discussed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11606369

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

Review 1.  Rapid changes in plant genomes.

Authors:  Steven Henikoff
Journal:  Plant Cell       Date:  2005-11       Impact factor: 11.277

2.  DNA polymerase beta null mouse embryonic fibroblasts harbor a homozygous null mutation in DNA polymerase iota.

Authors:  Robert W Sobol
Journal:  DNA Repair (Amst)       Date:  2006-09-18

3.  WRN protects against topo I but not topo II inhibitors by preventing DNA break formation.

Authors:  Markus Christmann; Maja T Tomicic; Christopher Gestrich; Wynand P Roos; Vilhelm A Bohr; Bernd Kaina
Journal:  DNA Repair (Amst)       Date:  2008-10-15

4.  Comparison of silk-elastinlike protein polymer hydrogel and poloxamer in matrix-mediated gene delivery.

Authors:  Robert Price; Joshua Gustafson; Khaled Greish; Joseph Cappello; Lawrence McGill; Hamidreza Ghandehari
Journal:  Int J Pharm       Date:  2011-10-01       Impact factor: 5.875

Review 5.  Circulating Tumor Cells in Breast Cancer Patients: A Balancing Act between Stemness, EMT Features and DNA Damage Responses.

Authors:  Benedikt Heitmeir; Miriam Deniz; Wolfgang Janni; Brigitte Rack; Fabienne Schochter; Lisa Wiesmüller
Journal:  Cancers (Basel)       Date:  2022-02-16       Impact factor: 6.639

6.  Alteration of the carbohydrate for deoxyguanosine analogs markedly changes DNA replication fidelity, cell cycle progression and cytotoxicity.

Authors:  Jessica J O'Konek; Brendon Ladd; Sheryl A Flanagan; Mike M Im; Paul D Boucher; Tico S Thepsourinthone; John A Secrist; Donna S Shewach
Journal:  Mutat Res       Date:  2010-01-08       Impact factor: 2.433

7.  c-Fos is required for excision repair of UV-light induced DNA lesions by triggering the re-synthesis of XPF.

Authors:  Markus Christmann; Maja T Tomicic; Judith Origer; Dorthe Aasland; Bernd Kaina
Journal:  Nucleic Acids Res       Date:  2006-11-27       Impact factor: 16.971

8.  MLH1 deficiency enhances tumor cell sensitivity to ganciclovir.

Authors:  J J O'Konek; P D Boucher; A A Iacco; T E Wilson; D S Shewach
Journal:  Cancer Gene Ther       Date:  2009-03-20       Impact factor: 5.987

9.  Apoptosis induced by temozolomide and nimustine in glioblastoma cells is supported by JNK/c-Jun-mediated induction of the BH3-only protein BIM.

Authors:  Maja T Tomicic; Ruth Meise; Dorthe Aasland; Nancy Berte; Rebekka Kitzinger; Oliver H Krämer; Bernd Kaina; Markus Christmann
Journal:  Oncotarget       Date:  2015-10-20
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.